2,226,138 Shares in BioNTech SE Sponsored ADR $BNTX Bought by Flossbach Von Storch SE

Posted by on Aug 20th, 2026

Flossbach Von Storch SE acquired a new stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,226,138 shares of the company’s stock, valued at approximately $207,142,000.

Other institutional investors have also added to or reduced their stakes in the company. PensionDanmark Pensionsforsikringsaktieselskab increased its holdings in shares of BioNTech by 10.9% during the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 8,290 shares of the company’s stock worth $771,000 after buying an additional 816 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of BioNTech in the second quarter valued at about $39,385,000. Bank of America Corp DE raised its position in shares of BioNTech by 22.6% during the first quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock worth $80,261,000 after acquiring an additional 166,432 shares during the last quarter. Amundi lifted its stake in shares of BioNTech by 24.5% in the first quarter. Amundi now owns 129,513 shares of the company’s stock worth $11,511,000 after acquiring an additional 25,506 shares during the period. Finally, Royal Bank of Canada lifted its stake in shares of BioNTech by 15.5% in the first quarter. Royal Bank of Canada now owns 46,991 shares of the company’s stock worth $4,177,000 after acquiring an additional 6,308 shares during the period. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Trading Up 22.0%

NASDAQ:BNTX opened at $113.12 on Thursday. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $28.61 billion, a price-to-earnings ratio of -14.45 and a beta of 1.27. The firm has a fifty day simple moving average of $92.48 and a two-hundred day simple moving average of $95.66. BioNTech SE Sponsored ADR has a 12 month low of $79.52 and a 12 month high of $124.00.

BioNTech (NASDAQ:BNTX – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The company had revenue of $166.40 million during the quarter, compared to the consensus estimate of $180.18 million. During the same period last year, the firm posted ($1.60) earnings per share. The company’s revenue for the quarter was down 59.5% on a year-over-year basis. Analysts expect that BioNTech SE Sponsored ADR will post -6.33 EPS for the current fiscal year.

BioNTech declared that its board has authorized a share repurchase program on Thursday, May 7th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the company to repurchase up to 4.2% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s board believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Berenberg Bank decreased their target price on shares of BioNTech from $155.00 to $140.00 and set a “buy” rating for the company in a research report on Tuesday, May 12th. Citigroup dropped their price target on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating on the stock in a research report on Wednesday, August 5th. Morgan Stanley reduced their price objective on shares of BioNTech from $126.00 to $119.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 8th. Wall Street Zen cut shares of BioNTech from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, UBS Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $117.00 to $135.00 in a research note on Wednesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $127.81.

View Our Latest Analysis on BioNTech

About BioNTech

(Free Report)

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

Featured Stories

Want to see what other hedge funds are holding BNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioNTech SE Sponsored ADR (NASDAQ:BNTX – Free Report).

Institutional Ownership by Quarter for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.